stem cell-based approach for the treatment of parkinson's disease

parkinson’s disease (pd) is the second most common neurodegenerative brain disorder which is around 1.5 times more common in men than in women. currently, drug medications, surgery, and lifestyle changes are common approaches to pd, while all of them focused on reducing the symptoms. therefore, regenerative medicine based on stem cell (sc) therapies has raised a promising hope. various types of scs have been used in basic and experimental studies relevant to pd, including embryonic pluripotential stem cells, mesenchymal (mscs) and induced pluripotent scs (ipscs). mscs have several advantages over other counterparts. they are easily accessible which can be obtained from various tissues such as bone marrow, adipose tissue, peripheral blood, etc. with avoiding ethical problems. therefore, mscs is attractive clinically because there are no related ethical and immunological concerns . further studies are needed to answer some crucial questions about the different issues in sc therapy. accordingly, sc-based therapy for pd also needed more complementary evaluation in both basic and clinical study areas.